John K Camoriano, MD

  • 2641 Citations
  • 27 Scopus h-Index
1982 …2018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where John K Camoriano is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 27 Similar Profiles
Primary Myelofibrosis Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Giant Lymph Node Hyperplasia Medicine & Life Sciences
Prednisone Medicine & Life Sciences
Factor X Deficiency Medicine & Life Sciences
Cisplatin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1982 2018

  • 2641 Citations
  • 27 Scopus h-Index
  • 46 Article
  • 2 Letter

PET/TC con 18F-FDG en la detección de adenocarcinoma oculto de vesícula biliar que se presenta como tumores de Krukenberg ováricos bilaterales

Translated title of the contribution: 18F-FDG PET/CT in detection of occult gallbladder adenocarcinoma presenting as bilateral ovarian Krukenberg tumorsJamison, D. K., Butler, K. A., Stucky, C. C. H., Camoriano, J. K. & Yang, M., Jan 1 2018, (Accepted/In press) In : Revista Espanola de Medicina Nuclear e Imagen Molecular.

Research output: Contribution to journalArticle

Krukenberg Tumor
Fluorodeoxyglucose F18
5 Citations (Scopus)

A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy

Rosenthal, A., Dueck, A., Ansell, S. M., Gano, K., Conley, C., Nowakowski, G. S., Camoriano, J. K., Leis, J. F., Mikhael, J. R., Stewart, A. K., Inwards, D., Dingli, D. M., Kumar, S. K., Noel, P., Gertz, M., Porrata, L., Russell, S. J., Colgan, J., Fonseca, R., Habermann, T. M. & 6 others, Kapoor, P., Buadi, F., Leung, N., Tiedemann, R., Witzig, T. E. & Reeder, C., May 1 2017, In : American Journal of Hematology. 92, 5, p. 467-472 6 p.

Research output: Contribution to journalArticle

Non-Hodgkin's Lymphoma
B-Cell Lymphoma
11 Citations (Scopus)

Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis

Gowin, K., Kosiorek, H., Dueck, A., Mascarenhas, J., Hoffman, R., Reeder, C., Camoriano, J. K., Tibes, R., Gano, K., Palmer, J. & Mesa, R., Sep 1 2017, In : Leukemia Research. 60, p. 31-35 5 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
10 Citations (Scopus)

Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial

Gowin, K., Jain, T., Kosiorek, H., Tibes, R., Camoriano, J. K., Palmer, J. & Mesa, R., Mar 1 2017, In : Leukemia Research. 54, p. 73-77 5 p.

Research output: Contribution to journalArticle

Clinical Trials
Polycythemia Vera
Primary Myelofibrosis
83 Citations (Scopus)

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

Bogenberger, J. M., Kornblau, S. M., Pierceall, W. E., Lena, R., Chow, D., Shi, C. X., Mantei, J., Ahmann, G., Gonzales, I. M., Choudhary, A., Valdez, R., Camoriano, J. K., Fauble, V., Tiedemann, R. E., Qiu, Y. H., Coombes, K. R., Cardone, M., Braggio, E. D., Yin, H., Azorsa, D. O. & 3 others, Mesa, R. A., Stewart, A. K. & Tibes, R., 2014, In : Leukemia. 28, 8, p. 1657-1665 9 p.

Research output: Contribution to journalArticle

RNA Interference
Small Interfering RNA